CTLA4 and neoplasm: The development of acquired resistance in FDA-approved CTLA-4 and PD-1 immunosuppressive antibodies triggers to search for additional more effective therapeutic strategies so that the efficacy of PD-1 or PD-L1 blockade pathway can enhance T cell immune response in contrast to tumor cells [48].